Jogler Christian, Hoffmann Dennis, Theegarten Dirk, Grunwald Thomas, Uberla Klaus, Wildner Oliver
Department of Molecular and Medical Virology, Ruhr-University Bochum, D-44801 Bochum, Germany.
J Virol. 2006 Apr;80(7):3549-58. doi: 10.1128/JVI.80.7.3549-3558.2006.
Oncolytic adenoviruses have emerged as a promising approach for the treatment of tumors resistant to other treatment modalities. However, preclinical safety studies are hampered by the lack of a permissive nonhuman host. Screening of a panel of primary cell cultures from seven different animal species revealed that porcine cells support productive replication of human adenovirus type 5 (Ad5) nearly as efficiently as human A549 cells, while release of infectious virus by cells from other animal species tested was diminished by several orders of magnitude. Restriction of productive Ad5 replication in rodent and rabbit cells seems to act primarily at a postentry step. Replication efficiency of adenoviral vectors harboring different E1 deletions or mutations in porcine cells was similar to that in A549 cells. Side-by-side comparison of the viral load kinetics in blood of swine and mice injected with Ad5 or a replication-deficient adenoviral vector failed to provide clear evidence for virus replication in mice. In contrast, evidence suggests that adenovirus replication occurs in swine, since adenoviral late gene expression produced a 13.5-fold increase in viral load in an individual swine from day 3 to day 7 and 100-fold increase in viral DNA levels in the Ad5-infected swine compared to the animal receiving a replication-deficient adenovirus. Lung histology of Ad5-infected swine revealed a severe interstitial pneumonia. Although the results in swine are based on a small number of animals and need to be confirmed, our data strongly suggest that infection of swine with human adenovirus or oncolytic adenoviral vectors is a more appropriate animal model to study adenoviral pathogenicity or pharmacodynamic and toxicity profiles of adenoviral vectors than infection of mice.
溶瘤腺病毒已成为治疗对其他治疗方式耐药肿瘤的一种有前景的方法。然而,由于缺乏允许性非人类宿主,临床前安全性研究受到阻碍。对来自七种不同动物物种的一组原代细胞培养物进行筛选发现,猪细胞支持人5型腺病毒(Ad5)的有效复制,其效率几乎与人A549细胞相同,而测试的其他动物物种细胞释放的感染性病毒减少了几个数量级。啮齿动物和兔细胞中Ad5有效复制的限制似乎主要作用于进入后阶段。在猪细胞中携带不同E1缺失或突变的腺病毒载体的复制效率与A549细胞中的相似。对注射Ad5或复制缺陷腺病毒载体的猪和小鼠血液中病毒载量动力学进行并列比较,未能为小鼠体内病毒复制提供明确证据。相比之下,有证据表明腺病毒在猪体内发生复制,因为腺病毒晚期基因表达使一只猪的病毒载量从第3天到第7天增加了13.5倍,与接受复制缺陷腺病毒的动物相比,Ad5感染猪的病毒DNA水平增加了100倍。Ad5感染猪的肺部组织学显示严重的间质性肺炎。尽管在猪身上的结果基于少数动物且需要进一步证实,但我们的数据强烈表明,与感染小鼠相比,用人腺病毒或溶瘤腺病毒载体感染猪是研究腺病毒致病性或腺病毒载体药效学和毒性特征更合适的动物模型。